



(11)

**EP 2 774 935 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:  
**C07K 14/47** <sup>(2006.01)</sup> **A61K 38/17** <sup>(2006.01)</sup>  
**A61P 25/00** <sup>(2006.01)</sup> **C07K 14/475** <sup>(2006.01)</sup>

(48) Corrigendum issued on:  
**21.06.2017 Bulletin 2017/25**

(45) Date of publication and mention  
of the grant of the patent:  
**19.04.2017 Bulletin 2017/16**

(21) Application number: **14165977.1**

(22) Date of filing: **28.10.2010**

(54) **Improved neurturin molecules**  
Verbesserte Neurturinmoleküle  
Molécules de neurturine améliorée

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **30.10.2009 US 256352 P**

(43) Date of publication of application:  
**10.09.2014 Bulletin 2014/37**

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
**10827453.1 / 2 493 918**

(73) Proprietor: **NTF Therapeutics, Inc.**  
**Chicago, IL 60615 (US)**

(72) Inventors:  
• **Runeberg-Roos, Pia**  
**Woodbury, MN Minnesota 55125 (US)**  
• **Bespalov, Maxim**  
**Woodbury, MN Minnesota 55125 (US)**  
• **Penn, Richard**  
**Woodbury, MN Minnesota 55125 (US)**  
• **Saarma, Mart**  
**Woodbury, MN Minnesota 55125 (US)**

(74) Representative: **Boult Wade Tennant**  
**Verulam Gardens**  
**70 Gray's Inn Road**  
**London WC1X 8BT (GB)**

(56) References cited:  
**WO-A1-97/08196 WO-A2-2009/059755**

- **HAMILTON J F ET AL: "Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin", EXPERIMENTAL NEUROLOGY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 168, no. 1, 1 March 2001 (2001-03-01), pages 155-161, XP002409643, ISSN: 0014-4886, DOI: 10.1006/EXNR.2000.7571**
- **HILEMAN R E ET AL: "Glycosaminoglycan-protein interactions: Definition of consensus sites in glycosaminoglycan binding proteins", BIOESSAYS, JOHN WILEY & SONS LTD, GB, vol. 20, no. 2, 1 February 1998 (1998-02-01), pages 156-167, XP002276571, ISSN: 0265-9247, DOI: 10.1002/(SICI)1521-1878(199802)20:2<156::A ID-BIES8>3.0.CO;2-R**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 774 935 B8**

- PILTONEN M ET AL: "Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons", EXPERIMENTAL NEUROLOGY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 219, no. 2, 1 October 2009 (2009-10-01), pages 499-506, XP026583797, ISSN: 0014-4886, DOI: 10.1016/J.EXPNEUROL.2009.07.002 [retrieved on 2009-07-15]